Open AccessUlipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?
Author(s) -
Simone Ferrero,
Valerio Gaetano Vellone,
Fabio Barra,
Carolina Scala
Publication year - 2018
Publication title -
gynecologic and obstetric investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 63
eISSN - 1423-002X
pISSN - 0378-7346
DOI - 10.1159/000495347
Subject(s) - ulipristal acetate , medicine , myoma , hysteroscopy , leiomyoma , laparoscopy , uterine myomectomy , myometrium , medline , gynecology , surgery , general surgery , uterus , family planning , research methodology , population , environmental health , political science , law
Ulipristal acetate ([UPA], Esmya®) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA.